Bisphosphonate therapy: how long is long enough?
Author:
- 22 January 2015
- journal article
- Published by Springer Nature in Osteoporosis International
- Vol. 26 (5) , 1455-1457
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Residual effect after oral bisphosphonate treatment and healthy adherer effects—the Swedish adherence register analysis (SARA)Osteoporosis International, 2014
- Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative databaseClinicoEconomics and Outcomes Research, 2013
- Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug HolidayThe American Journal of Medicine, 2013
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Effect of Stopping Risedronate after Long-Term Treatment on Bone TurnoverThe Journal of Clinical Endocrinology & Metabolism, 2011
- Fracture risk remains reduced one year after discontinuation of risedronateOsteoporosis International, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- Changes in bone density and turnover after alendronate or estrogen withdrawalMenopause, 2004
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Increments in Bone Mineral Density of the Lumbar Spine and Hip and Suppression of Bone Turnover Are Maintained after Discontinuation of Alendronate in Postmenopausal WomenThe American Journal of Medicine, 1997